Vascular endothelial growth factor (VEGF) up-regulates epidermal growth factor receptor (EGF-R) in cervical cancer in vitro: this action is mediated through HPV-E6 in HPV-positive cancers.

Abstract:

OBJECTIVES:Epidermal Growth Factor Receptor (EGF-R) up-regulation in cervical cancer cells leads to an increase in cell proliferative Insulin-like Growth Factor II (IGF-II) and Vascular Endothelial Growth Factor (VEGF) and a decrease of the anti-proliferative IGF-binding protein-3 (IGF-BP3). The objectives for this study are: (a) to find if VEGF, in turn, up-regulates EGF-R and down-regulates IGF-BP3; (b) to determine if human papilloma virus (HPV-E6) mediates this action of VEGF in HPV-positive cells; and (c) to verify if these effects are reflected in changes in cell proliferation METHODS:We used HPV-positive HeLa (Black), ME-180 and CaSki (Caucasian) and HPV-negative HT-3 (Caucasian) cell lines. (a) Levels of HPV-E6 in the HPV-positive cells were enumerated after treating the cells for 24 h with 20 ng/ml of VEGF using our semi-quantitative immunofluorescent antibody assay. (b) Cellular levels of EGF-R, HPV-E6, IGF-II and IGF-BP3 were enumerated in ME-180 and CaSki cells incubated for 24 h with 5, 10 and 20 ng/ml of VEGF. (c) HPV-negative HT-3 and HPV-positive ME-180 and CaSki cells were incubated with 20 ng/ml VEGF alone or in combination with antibodies to HPV-E6 and EGF-R. HPV-E6 (measured only in HPV-positive cells), EGF-R, IGF-II and IGF-BP3 levels were measured. (d) Cell proliferation was determined using cell proliferation Bradykinine-U colorimetric assay, in HT-3, HeLa and ME-180 cell lines in the presence of VEGF alone and with HPV-E6 antibodies. RESULTS:(a) In all the HPV-positive cell lines, 20 ng/ml VEGF significantly increased (30-50%; P < 0.0001) the HPV-E6. (b) In the ME-180 and CaSki cells, VEGF treatment up-regulated EGF-R, IGF-II and HPV-E6 and down-regulated IGF-BP3 in a dose-dependent manner (P < 0.001). (c) These effects of VEGF were eliminated when the HPV-positive cells were co-incubated with antibodies to HPV-E6 or EGF-R. In the HPV-negative HT-3 cells, VEGF decreased IGF-BP3 while increasing EGF-R and IGF-II levels. Antibodies to EGF-R eliminated these effects (P < 0.0001). (d) Treatment with VEGF resulted in increased cell proliferation in HT-3, HeLa and ME-180 cells; co-incubation with HPV-E6 antibodies abrogated this effect only in the HPV-positive cells. CONCLUSIONS:In cervical cancer, VEGF up-regulates EGF-R and down-regulates IGF-BP3, thus amplifying the cell proliferative activity of EGF-R. This action of VEGF seems to be mediated, directly through EGF-R or indirectly through HPV-E6 in the HPV-positive cancers, while EGF-R up-regulation appears to play a major role in the HPV-negative cervical cancers.

journal_name

Gynecol Oncol

journal_title

Gynecologic oncology

authors

Mathur RS,Mathur SP

doi

10.1016/j.ygyno.2004.12.011

subject

Has Abstract

pub_date

2005-04-01 00:00:00

pages

206-13

issue

1

eissn

0090-8258

issn

1095-6859

pii

S0090-8258(04)01004-2

journal_volume

97

pub_type

杂志文章
  • Detection and quantitation of human papillomavirus type 16, 18 and 52 DNA in the peripheral blood of cervical cancer patients.

    abstract:OBJECTIVE:To prospectively evaluate the feasibility of detecting human papillomavirus (HPV) type 16, 18 and 52 DNA in the peripheral blood of patients with cervical cancer using real-time polymerase chain reaction (PCR) and to determine its prognostic importance. METHODS:Blood and cervical swab specimens from 135 cons...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2005.07.004

    authors: Ho CM,Yang SS,Chien TY,Huang SH,Jeng CJ,Chang SF

    更新日期:2005-12-01 00:00:00

  • Neoadjuvant chemotherapy is associated with more anemia and perioperative blood transfusions than primary debulking surgery in women with advanced stage ovarian cancer.

    abstract:OBJECTIVE:The purpose of this case-controlled study was to determine the prevalence of anemia and incidence of perioperative blood transfusions in patients undergoing treatment for advanced ovarian cancer with neoadjuvant chemotherapy (NACT) or primary debulking surgery (PDS). METHODS:We performed a single institution...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2018.05.014

    authors: O'Shea A,McCool K,Harrison R,Sampene E,Connor J,Barroilhet L

    更新日期:2018-07-01 00:00:00

  • Adjuvant chemotherapy with cisplatin, doxorubicin, and cyclophosphamide (PAC) for early-stage high-risk endometrial cancer: a preliminary analysis.

    abstract::Between October 1985 and January 1989, 33 patients with stage I (31) or clinically occult stage II (2) endometrial cancer at a high risk for recurrence were entered in a prospective study evaluating adjuvant cisplatin, doxorubicin, and cyclophosphamide (PAC) chemotherapy. Eligibility criteria included grade 2 tumors w...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/0090-8258(90)90063-q

    authors: Stringer CA,Gershenson DM,Burke TW,Edwards CL,Gordon AN,Wharton JT

    更新日期:1990-09-01 00:00:00

  • FDG PET/CT in staging of advanced epithelial ovarian cancer: frequency of supradiaphragmatic lymph node metastasis challenges the traditional pattern of disease spread.

    abstract:OBJECTIVE:Epithelial ovarian cancer (EOC) spreads intra-abdominally and to the retroperitoneal lymph nodes. A greater number of distant metastases are revealed by (18)F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) compared to conventional imaging methods. We aimed to investigate th...

    journal_title:Gynecologic oncology

    pub_type: 临床试验,杂志文章

    doi:10.1016/j.ygyno.2012.04.023

    authors: Hynninen J,Auranen A,Carpén O,Dean K,Seppänen M,Kemppainen J,Lavonius M,Lisinen I,Virtanen J,Grénman S

    更新日期:2012-07-01 00:00:00

  • Antiemetic treatment of chemotherapy-induced nausea in ovarian carcinoma patients.

    abstract::In a prospective, randomized, double-blind trial the combination betamethasone-dixyrazine was compared with high-dose metoclopramide as antiemetic treatment during combination chemotherapy (melphalan-doxorubicin and cisplatin) of ovarian carcinoma. Of 40 evaluable patients, 15 (38%) had previous experience with chemot...

    journal_title:Gynecologic oncology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1016/0090-8258(89)90129-7

    authors: Sorbe B,Hallén C

    更新日期:1989-08-01 00:00:00

  • Reproducibility in the assessment of postmenopausal ovaries with transvaginal ultrasound.

    abstract:OBJECTIVE:The goal of this study was to evaluate the interexaminer variation in the assessment of postmenopausal ovaries using transvaginal ultrasound (TVU). METHODS:One hundred eighty-eight cancer screening trial participants undergoing TVU were reassessed by a second TVU examination. RESULTS:Although first examiner...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1006/gyno.2000.5785

    authors: Modugno F,Weissfeld JL,Hill LM

    更新日期:2000-05-01 00:00:00

  • HLA-DQB1 and cervical cancer in Venezuelan women.

    abstract:BACKGROUND:Cervical cancer represents a major health problem in Venezuela as well as in other Latin American countries. High-risk human papillomavirus (HR-HPV) infection is known as the major risk factor of cervical cancer. However, whether or not a HR-HPV-infected woman progresses to cervical cancer may depend on the ...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2004.10.002

    authors: Dao DD,Sierra-Torres CH,Robazetti SC,de Gomez MN,König R,Lema C,Lester LJ,Au WW,Tyring SK

    更新日期:2005-02-01 00:00:00

  • Gene expression profiling of in vitro radiation resistance in cervical carcinoma: a feasibility study.

    abstract:OBJECTIVE(S):To determine the feasibility of integrating an in vitro chemo-radiation response assay (IVRRA) with a gene microarray system to investigate the molecular patterns of expression that contribute to radiation resistance in cervical cancer. METHODS:Viable primary untreated cervical cancer specimens were obtai...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2005.05.043

    authors: Tewari D,Monk BJ,Al-Ghazi MS,Parker R,Heck JD,Burger RA,Fruehauf JP

    更新日期:2005-10-01 00:00:00

  • Mucinous adenocarcinoma arising in rectovaginal fistulas associated with Crohn's disease.

    abstract:BACKGROUND:Crohn's disease is a chronic inflammatory disorder characterized by focal, transmural inflammation of the intestine. Gynecologic involvement, including rectovaginal fistula formation, is frequent. Case #1. A 53-year-old female with a 30-year history of Crohn's disease and numerous perirectal fistulas develop...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2003.11.056

    authors: Moore-Maxwell CA,Robboy SJ

    更新日期:2004-04-01 00:00:00

  • Primary non-Hodgkin's lymphoma in Bartholin's gland.

    abstract:BACKGROUND:Non-Hodgkin's lymphoma (NHL) may involve the lower female genital tract, most often as a manifestation of systemic disease and rarely as a primarily localisation. CASE:A 73-year-old woman, HIV-negative, presented with a 5-month history of a mass in the left Bartholin's gland. The performed biopsy was report...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1006/gyno.2002.6828

    authors: Tjalma WA,Van de Velde AL,Schroyens WA

    更新日期:2002-12-01 00:00:00

  • Brain metastases in patients with EOC: Clinico-pathological and prognostic factors. A multicentric retrospective analysis from the MITO group (MITO 19).

    abstract:BACKGROUND:Brain metastases (BM) from epithelial ovarian cancer (EOC) are considered a rare and unfavourable event. There is no consensus regarding the best management of these patients. METHODS:A multicenter retrospective analysis of patients with BM from EOC treated between 1997 and 2014 in 18 institutions of the MI...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章,多中心研究

    doi:10.1016/j.ygyno.2016.09.025

    authors: Marchetti C,Ferrandina G,Cormio G,Gambino A,Cecere S,Lorusso D,De Giorgi U,Bogliolo S,Fagotti A,Mammoliti S,Narducci F,Bergamini A,Scollo P,Biglia N,Breda E,Tamberi S,Marinaccio M,Angioli R,Salerno L,Eusebi MC,Loi

    更新日期:2016-12-01 00:00:00

  • Clinical characteristics of clear cell carcinoma of the ovary.

    abstract:OBJECTIVE:The aim of this study is to evaluate the clinical characteristics of clear cell carcinoma of the ovary. METHODS:Between 1986 and 1996, 45 patients with clear cell carcinoma of the ovary were identified by scanning the medical records department and the tumor registry at our institution. RESULTS:Median age w...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1006/gyno.1998.5071

    authors: Behbakht K,Randall TC,Benjamin I,Morgan MA,King S,Rubin SC

    更新日期:1998-08-01 00:00:00

  • Human cervical cells immortalized in vitro with oncogenic human papillomavirus DNA differentiate dysplastically in vivo.

    abstract::Human papillomavirus (HPV) types 16 and 18 are associated with cervical dysplasia and carcinoma. In vitro integration of HPV-16 or HPV-18 DNA into cultured human cervical cells results in their immortalization. In this study, in vivo differentiation of human cervical cells immortalized with recombinant HPV-16 or HPV-1...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/0090-8258(90)90082-v

    authors: Waggoner SE,Woodworth CD,Stoler MH,Barnes WA,Delgado G,DiPaolo JA

    更新日期:1990-09-01 00:00:00

  • Endometrial adenocarcinoma: clinical outcome in 881 patients and analysis of 146 patients whose deaths were due to endometrial cancer.

    abstract::Throughout 1970-1975, 881 patients were treated at Departments I and II of Obstetrics and Gynecology, Helsinki University Central Hospital. They were treated mainly by using surgery and/or radiotherapy combined with adjuvant progestin therapy. The over-all uncorrected 5-year survival rate was 72.2% and corrected rate ...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/0090-8258(86)90059-4

    authors: Tiitinen A,Forss M,Aho I,Vesterinen E,Nieminen U

    更新日期:1986-09-01 00:00:00

  • Durability of clinical performance afforded by self-collected HPV testing: A 15-year cohort study in China.

    abstract:OBJECTIVE:Self-collected HPV testing could substantially reduce disparities in cervical cancer screening, with slightly lower sensitivity compared to physician-collected specimens cross-sectionally. We aimed to evaluate the comprehensive long-term performance of self-collected HPV testing prospectively. METHODS:In 199...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2018.09.012

    authors: Zhang L,Xu XQ,Hu SY,Chen F,Zhang X,Pan QJ,Zhang WH,Feng RM,Dong L,Zhang Q,Ma JF,Sauvaget C,Zhao FH,Qiao YL,Sankaranarayanan R

    更新日期:2018-11-01 00:00:00

  • Risk-prediction model of severe postoperative complications after primary debulking surgery for advanced ovarian cancer.

    abstract:OBJECTIVES:To refine models to predict surgical morbidity and 90-day mortality after primary debulking surgery (PDS) for advanced epithelial ovarian cancer (EOC). METHODS:Women with stage IIIC/IV EOC who underwent PDS with curative intent between 1/2/2003 and 12/30/2011 were included. Patient characteristics, intraope...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2015.10.025

    authors: Kumar A,Janco JM,Mariani A,Bakkum-Gamez JN,Langstraat CL,Weaver AL,McGree ME,Cliby WA

    更新日期:2016-01-01 00:00:00

  • Alternative medicine in gynecologic oncology: A case report.

    abstract::A patient with Stage IIB squamous cell cancer of the cervix presented 10 days into her primary radiation therapy with neutropenic fever and diarrhea requiring hospitalization and delay in treatment. The patient's history revealed extensive use of alternative therapies including potential toxic botanicals. This case ra...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1006/gyno.2000.5743

    authors: von Gruenigen VE,Hopkins MP

    更新日期:2000-04-01 00:00:00

  • Ovarian endometrioid adenocarcinoma arising from an endometriotic cyst in a postmenopausal woman under tamoxifen therapy for breast cancer: a case report.

    abstract:BACKGROUND:Ovarian cancer arising from an endometriotic cyst in a postmenopausal woman under tamoxifen therapy is rare. CASE:We herein report the case of a 67-year-old woman with a history of breast cancer, taking tamoxifen citrate 20 mg/day for 4 years, who underwent an operation for left ovarian tumor. The postopera...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章,评审

    doi:10.1006/gyno.2002.6824

    authors: Okugawa K,Hirakawa T,Ogawa S,Kaku T,Nakano H

    更新日期:2002-11-01 00:00:00

  • Stage II endometrioid adenocarcinoma of the endometrium: clinical implications of cervical stromal invasion.

    abstract:OBJECTIVES:Endometrioid adenocarcinoma of the endometrium (EEC) is the most common histologic type of endometrial cancer, with stage being the most critical prognostic factor. Cervical involvement (CI), divided into IIA (epithelial involvement) and IIB (stromal invasion), is overall associated with decreased survival (...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2009.03.007

    authors: Orezzoli JP,Sioletic S,Olawaiye A,Oliva E,del Carmen MG

    更新日期:2009-06-01 00:00:00

  • Targeting CD133 in an in vivo ovarian cancer model reduces ovarian cancer progression.

    abstract:OBJECTIVES:While most women with ovarian cancer will achieve complete remission after treatment, the majority will relapse within two years, highlighting the need for novel therapies. Cancer stem cells (CSC) have been identified in ovarian cancer and most other carcinomas as a small population of cells that can self-re...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2013.05.027

    authors: Skubitz AP,Taras EP,Boylan KL,Waldron NN,Oh S,Panoskaltsis-Mortari A,Vallera DA

    更新日期:2013-09-01 00:00:00

  • Preoperative C-reactive protein serum levels as a predictive diagnostic marker in patients with adnexal masses.

    abstract:OBJECTIVE:To evaluate C-reactive protein (CRP) serum levels as a preoperative predictive marker for ovarian cancer in patients with adnexal masses. METHODS:CRP serum levels of 1843 adnexal masses and subsequent surgery were investigated (patients with benign ovarian tumors: n=1423; borderline tumor of the ovary [BTO]:...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2017.09.018

    authors: Reiser E,Aust S,Seebacher V,Reinthaller A,Helmy-Bader S,Schwameis R,Grimm C,Polterauer S

    更新日期:2017-12-01 00:00:00

  • Alterations in SPARC and VEGF immunoreactivity in epithelial ovarian cancer.

    abstract:OBJECTIVE:Secreted protein, acidic and rich in cysteine (SPARC), is a matricellular protein that modulates cell adhesion and growth. It is thought to play a decisive role in tissue remodeling and angiogenesis. Alterations in SPARC expression have been observed in a variety of solid tumors; however, no consistent patter...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1006/gyno.2000.5894

    authors: Paley PJ,Goff BA,Gown AM,Greer BE,Sage EH

    更新日期:2000-09-01 00:00:00

  • Effect of recombinant human tumor necrosis factor on A2774 human ovarian cancer cell line: potentiation of mitoxantrone cytotoxicity.

    abstract::Recombinant human tumor necrosis factor (rHuTNF) is a macrophage-secretory protein with antitumor activity. In vivo and in vitro cytotoxicity studies have been carried out to test the effectiveness of rHuTNF alone or in combination with chemotherapeutic agents. We have evaluated the direct cytotoxic effect of rHuTNF o...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/0090-8258(91)90254-3

    authors: Vigani A,Chiara S,Miglietta L,Repetto L,Conte PF,Cimoli G,Morelli L,Billi G,Parodi S,Russo P

    更新日期:1991-04-01 00:00:00

  • Inverse correlation between RASSF1A hypermethylation, KRAS and BRAF mutations in cervical adenocarcinoma.

    abstract:OBJECTIVE:Although the incidence of cervical adenocarcinoma is increasing, few genetic and epigenetic changes in its progression have been described. We hypothesized that RASSF1A methylation and KRAS and BRAF mutations may play an important role in cervical adenocarcinoma. METHODS:Archival primary carcinoma tissues (n...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2007.01.045

    authors: Kang S,Kim HS,Seo SS,Park SY,Sidransky D,Dong SM

    更新日期:2007-06-01 00:00:00

  • Analysis of morbidity in patients with endometrial cancer: is there a commitment to offer laparoscopy?

    abstract:OBJECTIVE:Benefits of laparoscopy over laparotomy in patients with endometrial cancer (EC) are well known. As many patients with EC carry co-morbid conditions, surgery is exposing them to increased risk of complications. A review of the patients with EC recruited so far in a clinical trial comparing laparoscopy to lapa...

    journal_title:Gynecologic oncology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1016/j.ygyno.2004.12.048

    authors: Tozzi R,Malur S,Koehler C,Schneider A

    更新日期:2005-04-01 00:00:00

  • Advanced ovarian carcinoma presenting with a cerebrovascular accident.

    abstract::Ovarian carcinoma usually presents in an indolent manner, most often nonspecifically with complaints of abdominal pain or swelling, bloating, constipation, anorexia, early satiety, and evidence of ascites. We present a case of ovarian cancer with a cerebrovascular accident (CVA) as the presenting symptom, with minimal...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1006/gyno.1998.5053

    authors: Shamonki MI,Squatrito RC,Welander CE

    更新日期:1998-08-01 00:00:00

  • Postsurgical surveillance of patients with FIGO stage I/II endometrial adenocarcinoma.

    abstract:OBJECTIVE:To examine the effect of postsurgical surveillance on survival of patients with FIGO stage I/II endometrial adenocarcinoma. METHODS:We examined the records of 354 patients who underwent primary surgical therapy for FIGO stage I/II endometrial adenocarcinoma. In patients who developed recurrent disease, we de...

    journal_title:Gynecologic oncology

    pub_type: 临床试验,杂志文章

    doi:10.1006/gyno.1995.1262

    authors: Berchuck A,Anspach C,Evans AC,Soper JT,Rodriguez GC,Dodge R,Robboy S,Clarke-Pearson DL

    更新日期:1995-10-01 00:00:00

  • Contracting for professional service agreements.

    abstract::A review of several professional service agreements (PSA) of managed care organizations which contract with gynecologic oncologists in the Southern California area demonstrates several distinct patterns of practice restrictions and financial benefits which can help guide the physician who is considering signing such a...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1006/gyno.1995.1204

    authors: Berman ML

    更新日期:1995-08-01 00:00:00

  • Rectus abdominis myocutaneous flap for primary vaginal reconstruction.

    abstract::Reconstructive procedures are being performed with increasing frequency in conjunction with pelvic exenterations and other radical gynecologic surgeries. The most common reconstructive procedures include continent urinary diversion, rectosigmoid anastomosis, and vaginal reconstruction. Historically, the gracilis myocu...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1006/gyno.1993.1298

    authors: Carlson JW,Soisson AP,Fowler JM,Carter JR,Twiggs LB,Carson LF

    更新日期:1993-12-01 00:00:00

  • Transitional cell carcinoma of the endometrium.

    abstract::Only one case of endometrial transitional cell carcinoma (TCC) has been previously reported in the literature. We report a second case. In both the previously reported case and in this case there was a separate focus of TCC in the adnexa. Both patients were treated with adjuvant whole pelvic radiation and are alive an...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1006/gyno.1996.0047

    authors: Spiegel GW,Austin RM,Gelven PL

    更新日期:1996-02-01 00:00:00